Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities
Barbara Merelli(Ospedale Papa Giovanni XXIII), Mario Mandalà(University of Perugia), Daniela Massi(University of Florence), Laura Cattaneo(Ospedale Papa Giovanni XXIII)
Cited by 170
Related Papers
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway
|Archives of Pathology & Laboratory Medicine|2020|485
<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
|Journal of Clinical Oncology|2012|460
WHO classification of skin tumours
|IARC eBooks|2018|422